UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults

Journal of acquired immune deficiency syndromes (1999), 2013-08, Vol.63 (4), p.449-455

2013

Volltextzugriff (PDF)

Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression

The New England journal of medicine, 2020-03, Vol.382 (12), p.1112-1123

2020

Volltextzugriff (PDF)

"It made me more confident that I have it under control": Patient and provider perspectives on moving to a two-drug ART regimen in the United States and Spain

PloS one, 2020-05, Vol.15 (5), p.e0232473-e0232473

2020

Volltextzugriff (PDF)

Efficacy and Freedom: Patient Experiences with the Transition from Daily Oral to Long-Acting Injectable Antiretroviral Therapy to Treat HIV in the Context of Phase 3 Trials

AIDS and behavior, 2020-12, Vol.24 (12), p.3473-3481

2020

Volltextzugriff (PDF)

Multi-level considerations for optimal implementation of long-acting injectable antiretroviral therapy to treat people living with HIV: perspectives of health care providers participating in phase 3 trials

BMC health services research, 2021-03, Vol.21 (1), p.255-255, Article 255

2021

Volltextzugriff (PDF)

"I feel empowered": women's perspectives on and experiences with long-acting injectable antiretroviral therapy in the USA and Spain

Culture, health & sexuality, 2021-08, Vol.23 (8), p.1066-1078

2021

Volltextzugriff (PDF)

Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults

Journal of acquired immune deficiency syndromes (1999), 2009-04, Vol.50 (4), p.367-374

2009

Volltextzugriff (PDF)

Pre-exposure prophylaxis (PrEP) for HIV infection: results of a survey of HIV healthcare providers evaluating their knowledge, attitudes, and prescribing practices

AIDS patient care and STDs, 2013-10, Vol.27 (10), p.553-559

2013

Volltextzugriff (PDF)

First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses

Retrovirology, 2016-11, Vol.13 (1), p.82-82, Article 82

2016

Volltextzugriff (PDF)

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

The Lancet (British edition), 2019-01, Vol.393 (10167), p.143-155

2019

Volltextzugriff (PDF)

Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial

JAMA : the journal of the American Medical Association, 2015-03, Vol.313 (12), p.1223

2015

Volltextzugriff (PDF)

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1

The New England journal of medicine, 2015-08, Vol.373 (8), p.705-713

2015

Volltextzugriff (PDF)

CCR5 antagonists in the treatment of treatment-naive patients infected with CCR5 tropic HIV-1

European journal of medical research, 2007-10, Vol.12 (9), p.427

2007

Volltextzugriff (PDF)

Role of GB virus C in HIV-1-infected and hepatitis C virus-infected hemophiliac children and adolescents

Journal of acquired immune deficiency syndromes (1999), 2012-10, Vol.61 (2), p.243-248

2012

Volltextzugriff (PDF)

The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single‐arm, open‐label study of etravirine and darunavir/ritonavir as dual therapy in HIV‐1‐infected early treatment‐experienced subjects

HIV medicine, 2015-05, Vol.16 (5), p.288-296

2015

Volltextzugriff (PDF)

2497. Women’s Perspectives on and Experiences with Long-acting Injectable Anti-retroviral Therapy in the United States and Spain: the Potential Role of Gender in Patient Preferences

Open forum infectious diseases, 2019-10, Vol.6 (Supplement_2), p.S866-S866

2019

Volltextzugriff (PDF)

Sword 1 and 2: Subgroup Analysis of 48 Week Results by Age, Race and Gender

Open forum infectious diseases, 2017-10, Vol.4 (suppl_1), p.S427-S427

2017

Volltextzugriff (PDF)

Switch to Stribild versus continuation of NVP or RPV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY‐NNRTI subgroup analysis

Journal of the International AIDS Society, 2014-11, Vol.17 (4 Suppl 3), p.19793-n/a

2014

Volltextzugriff (PDF)

Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV‐infected, therapy‐naïve patients: results of the EPIC study (CCR100136)

HIV medicine, 2009-02, Vol.10 (2), p.116-124

2009

Volltextzugriff (PDF)

Pneumocystis carinii Pneumonia Presenting as an Isolated Pulmonary Nodule in a Non-HIV-Infected Immunosuppressed Patient

Infectious diseases in clinical practice (Baltimore, Md.), 2002-05, Vol.11 (4), p.219-220

2002

Volltextzugriff (PDF)

1 – 21 von 21

Suche als RSS-Feed

Aktive Filter

SpracheEnglisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)
Mit Volltextzugriff
(14)

Publikationsform

Artikel
(21)

Erscheinungsjahr

n.n

Thema

Hiv
(16)
Human Immunodeficiency Virus
(15)
Science & Technology
(15)
Life Sciences & Biomedicine
(14)
Humans
(13)
Female
(12)
Male
(12)
Antiretroviral Drugs
(11)
Middle Aged
(11)
Adult
(10)
Drug Therapy
(9)
Hiv Infections - Drug Therapy
(9)
Antiretroviral Therapy
(8)
Drug Therapy, Combination
(8)
Clinical Trials
(7)
Infectious Diseases
(7)
Antiretroviral Agents
(6)
Hiv-1
(6)
Rna, Viral - Blood
(6)
Anti-Hiv Agents - Administration & Dosage
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults

Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression

"It made me more confident that I have it under control": Patient and provider perspectives on moving to a two-drug ART regimen in the United States and Spain

Efficacy and Freedom: Patient Experiences with the Transition from Daily Oral to Long-Acting Injectable Antiretroviral Therapy to Treat HIV in the Context of Phase 3 Trials

Multi-level considerations for optimal implementation of long-acting injectable antiretroviral therapy to treat people living with HIV: perspectives of health care providers participating in phase 3 trials

"I feel empowered": women's perspectives on and experiences with long-acting injectable antiretroviral therapy in the USA and Spain

Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults

Pre-exposure prophylaxis (PrEP) for HIV infection: results of a survey of HIV healthcare providers evaluating their knowledge, attitudes, and prescribing practices

First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1

CCR5 antagonists in the treatment of treatment-naive patients infected with CCR5 tropic HIV-1

Role of GB virus C in HIV-1-infected and hepatitis C virus-infected hemophiliac children and adolescents

The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single‐arm, open‐label study of etravirine and darunavir/ritonavir as dual therapy in HIV‐1‐infected early treatment‐experienced subjects

2497. Women’s Perspectives on and Experiences with Long-acting Injectable Anti-retroviral Therapy in the United States and Spain: the Potential Role of Gender in Patient Preferences

Sword 1 and 2: Subgroup Analysis of 48 Week Results by Age, Race and Gender

Switch to Stribild versus continuation of NVP or RPV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY‐NNRTI subgroup analysis

Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV‐infected, therapy‐naïve patients: results of the EPIC study (CCR100136)

Pneumocystis carinii Pneumonia Presenting as an Isolated Pulmonary Nodule in a Non-HIV-Infected Immunosuppressed Patient

Aktive Filter

Suchergebnisse filtern